TABLE 1.

Basic characteristics for nonhuman primates included in the study^a

Group no.	No. in group (no. survived)		Challenge time (mo)	Vaccine dilution
	Treated	Control
1	10 (8)	2 (0)	52	Undiluted
2	9 (9)	1 (0)	52	1:5
3	10 (6)	2 (0)	52	1:10
4	10 (5)	2 (1)	12	1:20
5	10 (4)	2 (1)	12	1:40
6	10 (8)	2 (0)	12	1:10
7	10 (6)	2 (1)	12	1:20
8	10 (9)	2 (1)	12	1:40
9	9 (6)	2 (1)	30	1:10
10	10 (10)	2 (0)	30	Undiluted
11	8 (8)	2 (1)	30	1:5
12	8 (7)	2 (1)	30	1:20
Total	114 (86)	23 (7)

^aA total of 137 rhesus macaques (Macaca mulatta) were included in the study. The animals were injected intramuscularly with a 0.5-ml human dose of AVA or saline-diluted AVA (treated) or saline (control) at 0, 1, and 6 months, followed by aerosol challenge with spores of B. anthracis Ames strain at month 12, 30, or 52.